CANF
Price
$1.32
Change
-$0.10 (-7.04%)
Updated
Dec 18, 04:59 PM (EDT)
OTLC
Price
$0.03
Change
-$0.00 (-0.00%)
Updated
Dec 17 closing price
69 days until earnings call
Ad is loading...

CANF vs OTLC

Header iconCANF vs OTLC Comparison
Open Charts CANF vs OTLCBanner chart's image
Can-Fite BioPharma
Price$1.32
Change-$0.10 (-7.04%)
Volume$182
CapitalizationN/A
Oncotelic Therapeutics
Price$0.03
Change-$0.00 (-0.00%)
Volume$291.65K
CapitalizationN/A
CANF vs OTLC Comparison Chart
Loading...
CANF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CANF vs. OTLC commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CANF is a Buy and OTLC is a Hold.

COMPARISON
Comparison
Dec 19, 2024
Stock price -- (CANF: $1.42 vs. OTLC: $0.03)
Brand notoriety: CANF and OTLC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CANF: 72% vs. OTLC: 106%
Market capitalization -- CANF: $8.67M vs. OTLC: $11M
CANF [@Biotechnology] is valued at $8.67M. OTLC’s [@Biotechnology] market capitalization is $11M. The market cap for tickers in the [@Biotechnology] industry ranges from $482.14B to $0. The average market capitalization across the [@Biotechnology] industry is $2.68B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CANF’s FA Score shows that 0 FA rating(s) are green whileOTLC’s FA Score has 1 green FA rating(s).

  • CANF’s FA Score: 0 green, 5 red.
  • OTLC’s FA Score: 1 green, 4 red.
According to our system of comparison, OTLC is a better buy in the long-term than CANF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CANF’s TA Score shows that 4 TA indicator(s) are bullish.

  • CANF’s TA Score: 4 bullish, 4 bearish.

Price Growth

CANF (@Biotechnology) experienced а -11.25% price change this week, while OTLC (@Biotechnology) price change was -27.82% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.67%. For the same industry, the average monthly price growth was -1.91%, and the average quarterly price growth was -1.42%.

Reported Earning Dates

CANF is expected to report earnings on Jun 01, 2023.

OTLC is expected to report earnings on Feb 26, 2025.

Industries' Descriptions

@Biotechnology (-6.67% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
OTLC($11M) has a higher market cap than CANF($8.67M). OTLC (-34.144) and CANF (-35.455) have similar YTD gains .
CANFOTLCCANF / OTLC
Capitalization8.67M11M79%
EBITDAN/AN/A-
Gain YTD-35.455-34.144104%
P/E RatioN/AN/A-
RevenueN/AN/A-
Total Cash995KN/A-
Total Debt40KN/A-
FUNDAMENTALS RATINGS
CANF vs OTLC: Fundamental Ratings
CANF
OTLC
OUTLOOK RATING
1..100
16
VALUATION
overvalued / fair valued / undervalued
1..100
44
Fair valued
49
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9815
PRICE GROWTH RATING
1..100
9050
P/E GROWTH RATING
1..100
10095
SEASONALITY SCORE
1..100
n/a95

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CANF's Valuation (44) in the Biotechnology industry is in the same range as OTLC (49) in the null industry. This means that CANF’s stock grew similarly to OTLC’s over the last 12 months.

CANF's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as OTLC (100) in the null industry. This means that CANF’s stock grew similarly to OTLC’s over the last 12 months.

OTLC's SMR Rating (15) in the null industry is significantly better than the same rating for CANF (98) in the Biotechnology industry. This means that OTLC’s stock grew significantly faster than CANF’s over the last 12 months.

OTLC's Price Growth Rating (50) in the null industry is somewhat better than the same rating for CANF (90) in the Biotechnology industry. This means that OTLC’s stock grew somewhat faster than CANF’s over the last 12 months.

OTLC's P/E Growth Rating (95) in the null industry is in the same range as CANF (100) in the Biotechnology industry. This means that OTLC’s stock grew similarly to CANF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CANF
RSI
ODDS (%)
Bullish Trend 3 days ago
76%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
79%
Momentum
ODDS (%)
Bearish Trend 3 days ago
80%
MACD
ODDS (%)
Bearish Trend 3 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
83%
Advances
ODDS (%)
Bullish Trend 8 days ago
80%
Declines
ODDS (%)
Bearish Trend 3 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
84%
Aroon
ODDS (%)
Bearish Trend 3 days ago
89%
View a ticker or compare two or three
Ad is loading...
CANF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME31.261.82
+6.18%
GameStop Corp
TSLA479.8616.84
+3.64%
Tesla
AAPL253.482.44
+0.97%
Apple
BTC.X106140.600000110.890625
+0.10%
Bitcoin cryptocurrency
SPY604.29-2.50
-0.41%
SPDR® S&P 500® ETF Trust

CANF and

Correlation & Price change

A.I.dvisor tells us that CANF and LGVN have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CANF and LGVN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CANF
1D Price
Change %
CANF100%
-5.96%
LGVN - CANF
30%
Poorly correlated
-2.20%
RNA - CANF
29%
Poorly correlated
-1.95%
RLMD - CANF
28%
Poorly correlated
-6.97%
ZLAB - CANF
25%
Poorly correlated
+3.02%
ARWR - CANF
25%
Poorly correlated
-0.45%
More

OTLC and

Correlation & Price change

A.I.dvisor tells us that OTLC and THAR have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that OTLC and THAR's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OTLC
1D Price
Change %
OTLC100%
-18.08%
THAR - OTLC
25%
Poorly correlated
+0.46%
DRUG - OTLC
20%
Poorly correlated
+2.40%
CANF - OTLC
20%
Poorly correlated
-5.96%
MMIRF - OTLC
15%
Poorly correlated
N/A
IUGNF - OTLC
6%
Poorly correlated
N/A
More